Global Artificial Intelligence (AI) in Cancer Diagnostic Market to Grow at a CAGR of 40.1% Through 2026

According to MarkNtel Advisors, the Global Artificial Intelligence (AI) in Cancer Diagnostic Market is expected to grow at a CAGR of 40.1% in the forecast period of 2021-26. The precision of AI in cancer diagnosis and the ability to predict the occurrence of the disease at an early stage is higher than the conventional method. Therefore, the adoption of AI technology in cancer diagnostics is significantly increasing.

Besides, AI uses a large dataset for analyzing and predicting the result. This large pool of data improves the diagnosis. Hence, the patient gets identified as high or low-risk groups through accurate data from AI, which helps medical professionals plan a patient-centric treatment, further states the research report, “Global Artificial Intelligence (AI) in Cancer Diagnostic Market Analysis, 2021.”

Get the report sample free: https://www.marknteladvisors.com/query/request-sample/ai-in-cancer-diagnostic-market.html

Key Questions Answered in the Study
1. What are the current and future trends in the Global Artificial Intelligence (AI) in Cancer Diagnostic market?
2. How has the industry been evolving in terms of geography and services adoption?
3. How has the competition been shaping across the globe, followed by their comparative factorial indexing?
4. What are the key growth drivers and challenges for the Global Artificial Intelligence (AI) in Cancer Diagnostic market?
5. What are the customer orientation, purchase behavior, and expectations from Artificial Intelligence (AI) in Cancer Diagnostic providers across Global?

Medical Research Institutes to Register Fastest Growth in the Global Artificial Intelligence (AI) in Cancer Diagnostic Market

Based on the End-user, the market bifurcates into Hospitals, Medical Research Institutes, Diagnostics Centers, and Contract Research Organizations. Medical Research Institutes play a vital role in the overall AI in Cancer Diagnostic Market. The segment growth attributes to the rising attention towards clinical trials for advancing medical research. Further, Hospitals also hold a significant market share as they have large patient footfall, which is surging the need for technologically advanced diagnostics.

“Global Artificial Intelligence (AI) in Cancer Diagnostic Market Analysis, 2021” highlights insights on the market potential & opportunities, along with business strategies to enhance the overall market growth. The report offers an overview of leading market players and their recent developments. Moreover, the report provides incredible market opportunities & emerging trends to help stakeholders make appropriate decisions before investing.

For detailed analysis: https://www.marknteladvisors.com/research-library/ai-in-cancer-diagnostic-market.html

AI in Cancer Diagnostics Market Witnessed Steady Growth in the US During 2016-20

The AI in Cancer Diagnostics Market witnessed a steady growth rate in the US during the past five years owing to the increasing rate of positive recovery results, fewer omission errors, and reduced dosage errors. Additionally, the proven benefits of integrating AI technology with the healthcare industry is another crucial pointer that contributed to the market growth in the US.

Furthermore, extraordinary developments by startup firms in the country have also been a driving force for the market. For instance, iCAD’s CEO Ken Ferry, reported that iCAD’s power look assessment 3.4 helps identify patients with reduced sensitivity to digital mammography because of having dense breast tissues. QuantX enables physicians to accurately detect breast lesions in less amount of time with the help of machine learning.

Share your requirements: https://www.marknteladvisors.com/query/request-customization/ai-in-cancer-diagnostic-market.html

Key Market Competitors
According to MarkNtel Advisors, the leading industry players in the Global Artificial Intelligence (AI) in Cancer Diagnostic Market are Pfizer, Therapixel, Sophia Genetics, Freenome, Tempus, Janssen Pharmaceutica, Path AI, Google Deep Mind, IBM, Microsoft, Cerner Corporation, RaySearch Laboratories, Flatiron, Oncology Analytics, Inc, Oncora Medical, and Others.

Market Segmentation:
1. By Application (Screening & Diagnosis, Tumor Identification, Treatment, Surveillance)
2. By Cancer Type (Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, Other (Pancreatic, Skin, Blood, etc.))
3. By End User (Hospitals, Medical Research Institutes, Diagnostics Centers, Contract Research Organizations)
4. By Geographic Region (North America, Latin America, Europe, Middle East & Africa, Asia Pacific)
5. By Countries (US, Canada, Mexico, Brazil, Germany, France, Spain, Italy, Russia, The UK, South Africa, Saudi Arabia, China, India, Japan, Australia, South Korea)
6. By Competitors (Pfizer, Therapixel, Sophia Genetics, Freenome, Tempus, Janssen Pharmaceutica, Path AI, Google Deep Mind, IBM, Microsoft, Cerner Corporation, RaySearch Laboratories, Flatiron, Oncology Analytics, Inc, Oncora Medical, Others)

MarkNtel Advisors
1147 88AVE, Delta, British Columbia, BC,V4C,3B8, CANADA
Email: sales@marknteladvisors.com
Tel: +1 604 800 2671
Website: https://www.marknteladvisors.com

About us:
MarkNtel Advisors is a leading research, consulting and data analytics firm that provides a wide range of strategic reports on diverse industry verticals to a substantial and varied client base that includes multinational corporations, financial institutions, governments, and individuals.

We specialize in niche industries and emerging geographies to support our clients in the formulation of strategies viz. Go to Market (GTM), product development, feasibility analysis, project scoping, market segmentation, competitive benchmarking, market sizing & forecasting, trend analysis, etc. in around 15 industry verticals to enable our clients in identifying attractive investment opportunities and maximizing ROI through an early mover advantage.

This release was published on openPR.